Skip to content

Supplier News

Pfizer to acquire Allergan for $160 billion

Pfizer to acquire Allergan for $160 billion

Pfizer Inc. plans to acquire Allergan Inc. for about $160 billion in the biggest deal ever in the health care sector. Pfizer said Monday that the transaction will allow the New York-based drug giant to relocate to Ireland to cut its U.S. tax burden. “The proposed combination of Pfizer

AmerisourceBergen’s Collis to become chairman

AmerisourceBergen’s Collis to become chairman

Steven Collis, president and chief executive officer of AmerisourceBergen Corp., has been named to succeed Richard Gozon as chairman. The company said Wednesday that Collis is slated to become chairman upon Gozon’s retirement at AmerisourceBergen’s annual shareholders meeting on March 3, 2016.

Global drug spending to climb steadily

Global drug spending to climb steadily

More than half of the world’s population will live in countries where medicine use will exceed one dose per person per day by 2020, up from 31% a decade ago, as the “medicine use gap” between developed and pharmerging markets narrows, the IMS Institute for Healthcare Informatics projects.

Perrigo shareholders nix Mylan bid

Perrigo shareholders nix Mylan bid

Shareholders of Perrigo Co. plc have rejected a hostile bid by Mylan N.V. to acquire the company in a deal valued at about $27 billion. Perrigo said Friday that shareholders holding more than 60% of its outstanding shares declined to tender into Mylan’s offer by the 8 a.m. ET deadline. The offer

AB InBev, SABMiller strike deal to merge

AB InBev, SABMiller strike deal to merge

Beer giants Anheuser-Busch InBev has reached an agreement to acquire SABMiller plc in a deal valued at about $108 billion. Clearing the way for the agreement was a deal for SABMiller to sell its 58% stake in its MillerCoors LLC joint venture to partner Molson Coors Brewing Co. for $12 billion.

N.J. governor signs biosimilars legislation

N.J. governor signs biosimilars legislation

New Jersey Gov. Chris Christie has approved legislation to create a pathway for the substitution of interchangeable biologic drugs, drawing praise from the Biotechnology Industry Organization (BIO) and BioNJ, a state biotechnology organization.